Evidence map›Paper›PMID 39854342›Full record

ArticlePloS one2025

Computational design of multi-epitope vaccine against Hepatitis C Virus infection using immunoinformatics techniques.

Sara Zubair, Fahed Parvaiz, Turki Abualait, Khalid Al-Regaiey, Tasneem Anwar, Mahnoor Zafar, Imdad Kaleem, Shahid Bashir

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Towards precision epitopes based vaccine againstBiochemistry and biophysics reports · 2025
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sara ZubairDepartment of Biosciences, COMSATS University Islamabad (CUI), Islamabad, Pakistan.
Fahed ParvaizDepartment of Biosciences, COMSATS University Islamabad (CUI), Islamabad, Pakistan.ORCID 0000-0002-4310-2870
Turki AbualaitCollege of Applied Medical Sciences, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
Khalid Al-RegaieyDepartment of Physiology, King Saud University, Riyadh, Saudi Arabia.
Tasneem AnwarDepartment of Biosciences, COMSATS University Islamabad (CUI), Islamabad, Pakistan.
Mahnoor ZafarDepartment of Biosciences, COMSATS University Islamabad (CUI), Islamabad, Pakistan.
Imdad KaleemDepartment of Biosciences, COMSATS University Islamabad (CUI), Islamabad, Pakistan.
Shahid BashirNeuroscience Center, King Fahad Specialist Hospital Dammam, Dammam, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis C Virus (HCV) is a blood borne pathogen that affects around 200 million individuals worldwide. Immunizations against the Hepatitis C Virus are intended to enhance T-cell responses and have been identified as a crucial component of successful antiviral therapy. Nevertheless, attempts to mediate clinically relevant anti-HCV activity in people have mainly failed, despite the vaccines present satisfactory progress. In this study, we used an array of immunoinformatics approaches to design a multiepitope peptide-based vaccine against HCV by emphasizing 6 conserved epitopes from viral protein NS5B. The potential epitopes were examined for their possible antigenic combination with each other along with GPGPG linkers using structural modeling and epitope-epitope interaction analysis. An adjuvant (β-defensin) was introduced to the N-terminus to increase the immunogenicity of the vaccine construct. Molecular dynamics simulation discloses the most stable structure of the proposed vaccine. The designed vaccine is potentially antigenic in nature and can form stable and significant interaction with both receptors TLR2 and TLR3. The vaccine construct was also subjected to In-Silico cloning which confirmed its expression efficiency in a vector. The findings indicate that the designed multi-epitope vaccine have a great potential for preclinical and clinical research, which is an important step in addressing the problems related to HCV infection.

Indexed as

Computational BiologyEpitopesHepacivirusHepatitis CViral Hepatitis VaccinesHumansImmunoinformaticsMolecular Dynamics SimulationRNA-Dependent RNA PolymeraseToll-Like Receptor 3Viral Nonstructural ProteinsEpitopesNS-5 protein, hepatitis C virusRNA-Dependent RNA PolymeraseToll-Like Receptor 3Viral Hepatitis VaccinesViral Nonstructural Proteins

Identifiers

PMID39854342
PMCPMC11759374

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.